Parc De Salut Mar
Clinical trials sponsored by Parc De Salut Mar, explained in plain language.
-
Zinc trial aims to boost immunity in HIV patients who Don't respond to standard drugs
Disease control Recruiting nowThis study tests whether high-dose zinc supplements can improve immune function in people with HIV who still have low CD4 counts despite successful antiretroviral therapy. 120 participants will receive either zinc or a placebo for 16 weeks. Researchers will measure changes in CD4…
Phase: NA • Sponsor: Parc de Salut Mar • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Massive spanish study aims to predict and prevent suicide attempts
Knowledge-focused Recruiting nowThis study follows about 3,600 people in Spain who have attempted suicide to learn what factors increase the risk of another attempt. Researchers will track participants over time, collect blood samples, and use smartphone tools to monitor mood changes. The goal is to find better…
Sponsor: Parc de Salut Mar • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New tool aims to measure life after stomach cancer surgery
Knowledge-focused Recruiting nowThis study translates and validates a Korean quality-of-life questionnaire (KOQUSS-40) for Spanish-speaking patients who had stomach cancer surgery. Researchers will enroll 505 adults who are at least one month past surgery and cancer-free. The goal is to create a reliable tool t…
Sponsor: Parc de Salut Mar • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Stroke rehab showdown: does more therapy mean better recovery?
Knowledge-focused Recruiting nowThis study follows 213 adults recovering from a first ischemic stroke to see if the intensity of inpatient rehabilitation (high vs. moderate) affects their functional recovery at six months. It also compares people whose stroke was linked to atrial fibrillation with those whose s…
Sponsor: Parc de Salut Mar • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Can your genes predict which eye drug works best?
Knowledge-focused Recruiting nowThis phase 3 trial is testing whether a person's genetic makeup influences how well they respond to two standard drugs for wet age-related macular degeneration: ranibizumab and bevacizumab. About 630 patients will receive one of the two drugs and be followed for three years. The …
Phase: PHASE3 • Sponsor: Parc de Salut Mar • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC